Applications of radiocomplexes with thiosemicarbazones and bis(thiosemicarbazones) in diagnostic and therapeutic nuclear medicine

Metallic radionuclides possess a variety of half-lives, emission types, energies, and branching ratios, making it possible to apply them as diagnostic and/or therapeutic agents. Mono(thiosemicarbazones) and bis (thiosemicarbazones) show wide pharmacological profile and ability to chelate metals forming stable complexes. In the present work the behaviors of different radiometal complexes with mono(thiosemicarbazones) and bis(thiosemicarbazones) as diagnostic and therapeutic radiopharmaceutical drug candidates are reported. In particular, the applications of metal complexes with bis(thiosemicarbazones) as diagnostic radiopharmaceuticals have mostly been focused on bis(thiosemicarbazonato)copper(II) complexes, due to the success of the hypoxia-selective PET imaging agent Cu-64(ATSM), H(2)ATSM = diacetyl-bis(N4-methylthiosemicarbazone). However, metal complexes with mono- and bis(thiosemicarbazones) have also been obtained with other radioisotopes, mainly Ga-67/68, (111/114)mIn and Tc-99m. Some of these complexes have shown promising results in the search for new radiopharmaceuticals with applications in diagnosis and therapy. (C) 2022 Elsevier B.V. All rights reserved.

Automated summary

Metallic radionuclides have diverse applications as diagnostic and therapeutic agents. This study reports the behavior of different radiometal complexes with mono(thiosemicarbazones) and bis(thiosemicarbazones) as potential radiopharmaceuticals. The application of bis(thiosemicarbazonato)copper(II) complexes as diagnostic radiopharmaceuticals has been successful, while other radioisotopes such as Ga-67/68, (111/114)mIn, and Tc-99m have also been used to obtain mono- and bis(thiosemicarbazone) complexes for potential diagnosis and therapy.